Q/C Technologies

QCLSNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$22.932 M

$2.92 +4.29%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$11.6M

Loss-making

Shares outstanding

7,853,429

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#12Insight Molecular DiagnosticsIMDX$156.0M
#13ImmucellICCC$99.5M
#14Q/C TechnologiesQCLS$22.9M
#15VolitionrxVNRX$9.34M
#16Trinity BiotechTRIB$8.39M

Where these numbers come from

Share counts and financials for Q/C Technologies are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.